Additional Metadata
Keywords BCR ABL protein, NUP214 protein, T cell leukemia, T lymphoblast, absence of side effects, acute lymphoblastic leukemia, adult, article, asparaginase, cancer regression, case report, chronic myeloid leukemia, cyclophosphamide, cytarabine, cytogenetics, dasatinib, daunorubicin, erythrocyte transfusion, febrile neutropenia, fluorescence in situ hybridization, fusion gene, gene amplification, human, imatinib, lymphocytic infiltration, male, methotrexate, mitoxantrone, mucosa inflammation, multiple cycle treatment, prednisone, priority journal, protein tyrosine kinase, recombinant granulocyte colony stimulating factor, thrombocyte transfusion, unclassified drug, vincristine
Persistent URL dx.doi.org/10.1038/leu.2008.318, hdl.handle.net/1765/18112
Citation
Deenik, W., Beverloo, H.B., van der Poel-van de Luytgaarde, S.C.P.A.M., Wattel, M.M., van Esser, J.W.J., Valk, P.J.M., & Cornelissen, J.J.. (2009). Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia, 23(3), 627–629. doi:10.1038/leu.2008.318